A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

Jorge Cortes, Hagop Kantarjian, Maher Albitar, Deborah Thomas, Stefan Faderl, Charles Koller, Guillermo Garcia-Manero, Francis Giles, Michael Andreeff, Susan O'Brien, Michael Keating, Elihu Estey

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen. METHODS. Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated. RESULTS. None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide. CONCLUSIONS. The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS.

Original languageEnglish (US)
Pages (from-to)1234-1241
Number of pages8
JournalCancer
Volume97
Issue number5
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Topotecan
Daunorubicin
Thalidomide
Myelodysplastic Syndromes
Cytarabine
Acute Myeloid Leukemia
Vascular Endothelial Growth Factor A
Therapeutics
Survival
Combination Drug Therapy
Chromosome Aberrations
Drug Therapy

Keywords

  • Acute myeloid leukemia
  • Angiogenesis
  • Myelodysplastic syndrome
  • Thalidomide
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. / Cortes, Jorge; Kantarjian, Hagop; Albitar, Maher; Thomas, Deborah; Faderl, Stefan; Koller, Charles; Garcia-Manero, Guillermo; Giles, Francis; Andreeff, Michael; O'Brien, Susan; Keating, Michael; Estey, Elihu.

In: Cancer, Vol. 97, No. 5, 01.03.2003, p. 1234-1241.

Research output: Contribution to journalArticle

Cortes, Jorge ; Kantarjian, Hagop ; Albitar, Maher ; Thomas, Deborah ; Faderl, Stefan ; Koller, Charles ; Garcia-Manero, Guillermo ; Giles, Francis ; Andreeff, Michael ; O'Brien, Susan ; Keating, Michael ; Estey, Elihu. / A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. In: Cancer. 2003 ; Vol. 97, No. 5. pp. 1234-1241.
@article{77ab2a4f565e45e381ae1e7ac48186f0,
title = "A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome",
abstract = "BACKGROUND. Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen. METHODS. Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated. RESULTS. None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide. CONCLUSIONS. The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS.",
keywords = "Acute myeloid leukemia, Angiogenesis, Myelodysplastic syndrome, Thalidomide, Vascular endothelial growth factor",
author = "Jorge Cortes and Hagop Kantarjian and Maher Albitar and Deborah Thomas and Stefan Faderl and Charles Koller and Guillermo Garcia-Manero and Francis Giles and Michael Andreeff and Susan O'Brien and Michael Keating and Elihu Estey",
year = "2003",
month = "3",
day = "1",
doi = "10.1002/cncr.11180",
language = "English (US)",
volume = "97",
pages = "1234--1241",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

AU - Cortes, Jorge

AU - Kantarjian, Hagop

AU - Albitar, Maher

AU - Thomas, Deborah

AU - Faderl, Stefan

AU - Koller, Charles

AU - Garcia-Manero, Guillermo

AU - Giles, Francis

AU - Andreeff, Michael

AU - O'Brien, Susan

AU - Keating, Michael

AU - Estey, Elihu

PY - 2003/3/1

Y1 - 2003/3/1

N2 - BACKGROUND. Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen. METHODS. Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated. RESULTS. None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide. CONCLUSIONS. The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS.

AB - BACKGROUND. Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen. METHODS. Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated. RESULTS. None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide. CONCLUSIONS. The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS.

KW - Acute myeloid leukemia

KW - Angiogenesis

KW - Myelodysplastic syndrome

KW - Thalidomide

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0037370702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037370702&partnerID=8YFLogxK

U2 - 10.1002/cncr.11180

DO - 10.1002/cncr.11180

M3 - Article

C2 - 12599230

AN - SCOPUS:0037370702

VL - 97

SP - 1234

EP - 1241

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -